Benzinga | Sep 27, 2021 06:32AM EDT

RBC Capital Maintains Sector Perform on Acceleron Pharma, Raises Price Target to $179

RBC Capital analyst Kennen MacKay maintains Acceleron Pharma (NASDAQ:XLRN) with a Sector Perform and raises the price target from $113 to $179.